Immunic, Inc.IMUXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +101.98% | +4.16% | +30.51% | +91.46% | +1626.97% |
| Weighted Average Shares Diluted Growth | +101.98% | +4.16% | +30.51% | +91.46% | +1626.97% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -2.70% | -56.36% | -60.45% | -100.00% | +502.63% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -24.74% | -80.30% | -28.98% | -37.15% | -41.15% |
| Book Value per Share Growth | -68.46% | +0.00% | -59.13% | -86.70% | +0.00% |
| Debt Growth | -24.74% | -13.72% | +2.51% | -85.98% | -31.87% |
| R&D Expense Growth | +12.10% | +14.93% | +16.62% | -6.35% | -11.79% |
| SG&A Expenses Growth | -2.88% | +3.38% | +28.12% | +37.30% | +7.01% |